
For more than two decades, the quality part of the Common Technical Document has followed the structure set by ICH M4Q. Its revision, M4Q(R2), changes[…]

Excipients make up most of the mass of many medicines, yet they are often the least scrutinised part of the supply chain. Since 2016, EU[…]

Not every pharmacovigilance report describes a medicine used as authorised. Overdose, abuse, misuse, off-label use and occupational exposure are what EU guidance calls “special situations”[…]

An eCTD dossier is not a single submission but a lifecycle of sequences that builds over the years a product is on the market. Managing[…]

Module 5 is usually the largest part of a marketing authorisation dossier, and assessors navigate it under time pressure. A complete tabular listing, study reports[…]

Module 4 holds the nonclinical study reports that support the safety of a medicine before and alongside clinical use. Its structure is fixed by ICH[…]

The CTD quality structure was first written with small molecules in mind, but biological medicines place very different demands on Module 3. Cell substrates, viral[…]

Most attention in Module 3 goes to the drug substance and drug product sections. Yet the appendices in 3.2.A and the regional information in 3.2.R[…]

Section 3.2.S.3 is where the applicant proves it knows exactly what the active substance is and what else comes with it. A thorough impurity discussion,[…]

Module 3.2.P.3 describes how the finished product is made and how the applicant knows the process works. EMA’s guideline on process validation for finished products[…]